Asset
TELITACICEPT
Vor Biopharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06456580 | phase3 | recruiting | 2024-07-17 | 2027-05-01 | Vor Biopharma | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) |
| NCT05306574 | phase3 | terminated | 2022-06-20 | 2025-01-06 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
| NCT06456567 | phase3 | withdrawn | 2024-09-01 | 2025-01-02 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) |
| NCT07404865 | phase3 | recruiting | 2026-02-26 | 2028-12-01 | Vor Biopharma | Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease |
FDA applications (0)
This company has no applications containing this asset.